Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
512 results about "Lectin" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Lectins are carbohydrate-binding proteins that are highly specific for sugar groups of other molecules. Lectins have a role in recognition on the cellular and molecular level and play numerous roles in biological recognition phenomena involving cells, carbohydrates, and proteins. Lectins also mediate attachment and binding of bacteria and viruses to their intended targets.
Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
A method for enhancing a binding activity of an antibody composition to Fcgamma receptor IIIa, which comprises modifying a complex N-glycoside-linked sugar chain which is bound to the Fc region of an antibody molecule; a method for enhancing an antibody-dependent cell-mediated cytotoxic activity of an antibody composition; a process for producing an antibody composition having an enhanced binding activity to Fcgamma receptor IIIa; a method for detecting the ratio of a sugar chain in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chain among total complex N-glycoside-linked sugar chains bound to the Fc region in an antibody composition; an Fc fusion protein composition produced by using a cell resistant to a lectin which recognizes a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through alpha-bond in a complex N-glycoside-linked sugar chain; and a process for producing the same.
Owner:KYOWA HAKKO KIRIN CO LTD
Microorganism detection and analysis using carbohydrate and lectin recognition
ActiveUS20080193965A1Bioreactor/fermenter combinationsBiological substance pretreatmentsMicroorganismQuartz crystal microbalance
Methods of binding and detecting a microorganism on a solid substrate. The microorganism is bound on a solid substrate covalently bound to a capture agent having a saccharide moiety. A lectin capable of binding to the microorganism and the saccharide moiety of the capture agent is added to the sample to bind the microorganism on the solid substrate. Further provided are biosensor devices, such as a quartz crystal microbalance (QCM) device or a surface plasmon resonance (SPR) device, that incorporate the solid substrate for the detection of microorganisms.
Owner:OAKLAND UNIVESITY
Galactoside inhibitors of galectins
InactiveUS7638623B2Process economyHigh affinityEsterified saccharide compoundsOrganic active ingredientsDiseaseMedicine
Owner:GALECTO BIOTECH
Oral delivery systems for microparticles
PCT No. PCT / AU92 / 00141 Sec. 371 Date Nov. 30, 1992 Sec. 102(e) Date Nov. 30, 1992 PCT Filed Apr. 2, 1992 PCT Pub. No. WO92 / 17167 PCT Pub. Date Oct. 15, 1992There are disclosed complexes and compositions for oral delivery of a substance or substances to the circulation or lymphatic drainage system of a host. The complexes of the invention comprise a microparticle coupled to at least one carrier, the carrier being capable of enabling the complex to be transported to the circulation or lymphatic drainage system via the mucosal epithelium of the host, and the microparticle entrapping or encapsulating, or being capable of entrapping or encapsulating, the substance(s). Examples of suitable carriers are mucosal binding proteins, bacterial adhesins, viral adhesins, toxin binding subunits, lectins, Vitamin B12 and analogues or derivatives of Vitamin B12 possessing binding activity to Castle's intrinsic factor.
Owner:ACCESS PHARMA
Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
ActiveUS20130266560A1Improve survivalReduced survival rateAntibody ingredientsImmunoglobulins against enzymesDiseasePharmaceutical medicine
Owner:UNIVERSITY OF LEICESTER +1
Binding molecules for the treatment of myeloid cell malignancies
InactiveUS20060177451A1Suitable diagnosisSuitable preventionAntibody mimetics/scaffoldsImmunoglobulins against cell receptors/antigens/surface-determinantsMalignancyDisease cause
The present invention provides a human C-type lectin, binding molecules that specifically bind to the human C-type lectin, nucleic acid molecules encoding the binding molecules or the human C-type lectin, compositions comprising the binding molecules or the human C-type lectin and methods of identifying or producing the binding molecules. The human C-type lectin is specifically expressed on myeloid cells and binding molecules capable of specifically binding to the human C-type lectin can be used in the diagnosis, prevention and / or treatment of neoplastic disorders and diseases.
Owner:JANSSEN VACCINES & PREVENTION BV
Flours produced from fungus myceliated grain
The present patent relates to a method for producing flours from grain myceliated with macroscopic fungi (mushrooms). These flours can be used to prepare food for human consumption, such as bread and biscuits, and for animal consumption, such as fodder. Active principles (ergosterol, beta glucan, linoleic and oleic acids, lectins), enzymes, proteins, amino acids, vitamins, mineral salts, inter alia, can also be extracted from these flours for use in the chemical, foodstuff and cosmetic industries, for producing phytotherapeutic agents, pharmaceuticals, textiles, paper products, pharmaceuticals and fodder for animals.
Owner:EMPRESA BRASILEIRA DE PESQUISA AGROPECUARIA EMBRAPA +2
Novel specific cell binders
The invention describes reagents and methods for specific binders to glycan structures of stem cells. Furthermore the invention is directed to screening of additional binding reagents against specific glycan epitopes on the surfaces of the stem cells. The preferred binders of the glycans structures includes proteins such as enzymes, lectins and antibodies.
Owner:GLYKOS FINLAND
Blood separation system and method for a dry test strip
InactiveUS20120282634A1Less brittleImprove hydrophilicityBiological material analysisEnzymology/microbiology apparatusGlass fiberAnimal science
A dry test strip layer for filtering red blood cells includes a Borosilicate Glass Fiber layer and lectin, impregnated in the borosilicate layer, such that the dry test strip is configured to filter red blood cells from a blood sample.
Owner:POLYMER TECH SYST
Antibody composition-containing medicament
A medicament for treating a patient who cannot be cured with a medicament comprising as an active ingredient an antibody composition produced by a cell unresistant to a lectin which recognizes a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex N-glycoside-linked sugar chain, which comprises as an active ingredient an antibody composition produced by a cell resistant to a lectin which recognizes a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex N-glycoside-linked sugar chain, and a method for screening the patient by using the medicament.
Owner:KYOWA HAKKO KIRIN CO LTD
Signal amplification method for surface plasmon resonance-based chemical detection
InactiveUS7405054B1Bioreactor/fermenter combinationsBiological substance pretreatmentsPeroxidaseLab-on-a-chip
The present invention provides methods and compositions for amplifying the detection signal in surface plasmon resonance (SPR)-based flow systems. The signal amplification methods comprise the use of well established marker systems that provide a precipitate. The marker systems include, for example, enzyme and nucleation systems. Enzymes suitable for use as a marker system include peroxidases and phosphatases. The amplification system is useful in any SPR-based detection system including microfluidic systems, e.g., “lab on a chip” systems and the like. The methods can comprise any SPR-based assay format, including typical immunoassay formats. The immunoassay formats can include competitive and sandwich assays. Analyte capture agents can include antibodies, lectins, carbohydrates, polynucleotides, receptor proteins, and the like.
Owner:UNIV OF WASHINGTON
Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
ActiveUS20120258095A1Improve survivalReduced survival rateAntibacterial agentsAntibody ingredientsPharmaceutical medicinePharmacology
In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.
Owner:UNIVERSITY OF LEICESTER
Novel carbohydrate profile compositions from human cells and methods for analysis and modification thereof
InactiveUS20100145032A1Blood/immune system cellsNon-embryonic pluripotent stem cellsEpitopeAntiendomysial antibodies
The invention describes reagents and methods for specific binders to glycan structures of stem cells. Furthermore the invention is directed to screening of additional binding reagents against specific glycan epitopes on the surfaces of the stem cells. The preferred binders of the glycans structures includes proteins such as enzymes, lectins and antibodies.
Owner:GLYKOS FINLAND
Biotype diets system: predicting food allergies by blood type
InactiveUS20060013773A1Ultrasonic/sonic/infrasonic diagnosticsAnalysis using chemical indicatorsGroup A - bloodAntigen
The invention is a diet-typing system for humans, including novel methods for diagnosis and treatment of food allergies and hypersensitivities. The diagnostic method correlates blood types (immunologically reactive antigens on RBC, skin and membranes) to four kinds of food allergies / hypersensitivities (IgE antibodies, IgG antibodies, T-cells, and Lectins). The results are used to identify and predict food allergies and hypersensitivities for six biological types (blood types A1, A2, B, O, A1B, and A2B), plus diet modifications for three subtypes (blood type Rh-negative, males and females). The treatment method uses the results to make food recommendations (to eat, limit, or avoid), based on the strength or classification of allergy scores, to mitigate the risk of food allergies and hypersensitivities in future persons. The diet-typing system presents the results on six diet cards, one for each blood type. The methods and resulting diets are unique, and differ substantially from prior inventions.
Owner:POWER LAURA W
Enhanced antiviral therapy methods and devices
InactiveUS20110218512A1Increase heightEasy treatmentOther blood circulation devicesMedical devicesHemodialysisHaemodialysis machine
Embodiments of the present invention relate to enhanced antiviral therapy methods, devices, and kits for treating viral infections. The disclosed enhanced antiviral therapy methods, devices, and kits enhance the efficacy of an antiviral therapy by administering a lectin affinity hemodialysis treatment to an individual suffering from viral infection in combination with the antiviral therapy.
Owner:AETHLON MEDICAL INC
Bone filler material
ActiveUS20100255115A1Facilitate re-hydrationPowder deliveryPeptide/protein ingredientsGellan gumSphingomonas elodea
Described are bone generation matrixes having an admixture of demineralized bone matrix (DBM) particles and / or bone chips in combination with at least one binding agent selected from the group consisting of alginate, lectin, pectin, gellan gum, starch, collagen and combinations thereof in an aqueous solvent, wherein the DBM particles and / or bone chips are present in an amount of at least 65% by dry weight and the ratio of the aqueous solvent to the dry weight of the DBM particles / bone chips and at least one binding agent is between about 1:1 to about 1:6.
Owner:WARSAW ORTHOPEDIC INC
Immunoactive Compositions for Improved Oral Delivery of Vaccines and Therapeutic Agents
InactiveUS20080226682A1Raise the ratioImprove absorption and bioavailabilitySsRNA viruses negative-senseBiocideEnzyme Inhibitor AgentIsoflavones
The present invention concerns methods and compositions for improved oral delivery of bioactive agents, such as vaccines. In preferred embodiments, the compositions comprise at least one lectin, saponin, polyunsaturated fatty acid and / or isoflavone. In further embodiments, the compositions may further comprise at least one protease inhibitor, buffer and / or surfactant. In more preferred embodiments, the lectins, saponins, fatty acids, isoflavones and / or protease inhibitors may be derived from extracts, homogenates, finely ground powders or derivatives of plant or animal material, such as beans, nuts, peas, fish meal or krill. The relative amounts of various naturally occurring materials contained in the compositions may be selected to optimize the concentrations of one or more lectins, saponins, polyunsaturated fatty acids and / or isoflavones. The compositions are of use for oral delivery of a wide variety of bioactive agents, particularly protein or peptide based agents.
Owner:PEROS SYST TECH
Compositions, Kits, and Methods for the Diagnosis, Prognosis, Monitoring, Treatment and Modulation of Post-Transplant Lymphoproliferative Disorders and Hypoxia Associated Angiogenesis Disorders Using Galectin-1
ActiveUS20130011409A1Modulate angiogenesisReduce the overall diameterOrganic active ingredientsFungiPost transplantAngiogenesis growth factor
The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.
Owner:DANA FARBER CANCER INST INC +3
Extract method for lectin of leguminous plants
A method for extracting bean phytohemagglutinin belongs to the extraction technical field of useful constituents of plants. The method is a water extraction method in which the extraction is performed at 40-60 DEG C based on the following steps: crushing bean seeds to 40-100 meshes, adding soak solution to extract bean husk at the temperature of 40-60 DEG C for 60-180min and then fish the bean husk, performing rough separation to remove bean dregs, centrifugally separating to obtain supernatant with the bean phytohemagglutinin, further performing separation and purification on the supernatant, condensing or drying the supernatant to obtain the phytohemagglutinin. Ultrasonic wave or microwave can be exerted in the whole or part of the extraction process, or the ultrasonic wave and the microwave are alternately exerted to perform auxiliary extraction. A traditional low-temperature soaking and low-temperature treatment method is completely discarded in the method, and practice proves that the method is a simple and efficient method for extracting the phytohemagglutinin in short time. Related detection proves that the obtained phytohemagglutinin can meet conventional experimental needs and medicinal needs. The method helps overcome the disadvantage of more chemical reagent composition residue and long extraction time of the products obtained by the prior art.
Owner:YUNNAN KANGZHOU BIOLOGICAL SCI & TECH
Method for the characterization of intermolecular interactions
The invention relates to a method for identifying in a sample molecules with the capacity to bind to the different members of a molecule library, wherein the molecules which are in the sample are fractionated based on a physicochemical property of the sample and subsequently transferred from the support in which said molecules have been separated to a second support in which the different members of the molecule library are grouped into microarrays such that they uniformly coat the surface of the support. This technique is especially interesting for the identification in a sample of glycoproteins with affinity for a lectin library as well as for the identification of compounds capable of modulating the glycosylation of proteins and for the rapid characterization of alterations in the glycosylation pattern of a sample of proteins, which can be useful in the diagnosis of diseases in which there are alterations in cell glycosylation.
Owner:CENT DE INVESTIGACION COOP & BIOMATERIALES CIC BIOMAGUNE
Compounds for Treatment of Complement Mediated Disorders
ActiveUS20180022767A1Dampen and inhibit detrimental complement activitySenses disorderNervous disorderDiseaseReperfusion injury
Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.
Owner:ACHILLION PHARMA INC
Methods for treating conditions associated with MASP-2 dependent complement activation
ActiveUS8951522B2Reduce adverse effectsInhibition of activationAntibacterial agentsSenses disorderBiological activationLectin
In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.
Owner:UNIVERSITY OF LEICESTER
Collectin-complement activating protein chimeras
InactiveUS20060188963A1Improve abilitiesUseful in treatmentAntibacterial agentsPeptide/protein ingredientsCollectinComplement system
The present invention relates to a fusion protein capable of activating the complement system, the fusion protein comprising a first polypeptide sequence derived from a lectin-complement pathway activating protein or a functional homologue thereof; and a second polypeptide sequence derived from a collectin or a functional homologue thereof; wherein said complement activating protein is not a collectin. A preferred fusion protein comprises amino acids of the L-ficolin sequence of FIG. 1 and amino acids of the MBL sequence shown in FIG. 2. The fusion protein is suitable for use in treatment consisting of creation, reconstitution, enhancing and / or stimulating the opsonic and / or bactericidal activity of the complement system, i.e. enhancing the ability of the immune defence to recognise and kill microbial pathogens, and accordingly, the invention relates to a medicament comprising the fusion protein, methods for producing said fusion protein and methods for treating diseases, in particular infections.
Owner:ENZON PHARM INC
Adjuvant immune therapy in the treatment of solid tumors through modulation of signaling pathways following engagement of humoral and cell mediated responses
InactiveUS20020187130A1Evaluating efficacyAccurate assessmentBiocideSaccharide peptide ingredientsAdjuvantWhite blood cell
Owner:KINDNESS GEORGE +2
Method of microorganism detection using carbohydrate and lectin recognition
ActiveUS8088596B2Bioreactor/fermenter combinationsBiological substance pretreatmentsMicroorganismQuartz crystal microbalance
Methods of binding and detecting a microorganism on a solid substrate. The microorganism is bound on a solid substrate covalently bound to a capture agent having a saccharide moiety. A lectin capable of binding to the microorganism and the saccharide moiety of the capture agent is added to the sample to bind the microorganism on the solid substrate. Further provided are biosensor devices, such as a quartz crystal microbalance (QCM) device or a surface plasmon resonance (SPR) device, that incorporate the solid substrate for the detection of microorganisms.
Owner:OAKLAND UNIVESITY
Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
InactiveUS20060140939A1Avoid tissue damageReduce morbidityPeptide/protein ingredientsImmunoglobulins against animals/humansThoracoabdominal Aortic AneurysmsComplement lectin pathway
A method for preventing or treating tissue damage associated with ischemia-reperfusion injury and thoraco-abdominal aortic aneurysm (TAAA) repair by administering a tissue damage preventing or treating amount of a complement inhibitor to a patient likely to suffer from or suffering from tissue damage associated with ischemia-reperfusion injury or TAAA repair. The complement inhibitors are preferably antibodies that bind to and inhibit complement proteins involved in the formation of the membrane attach complex, preferably antibodies that inhibit MBL, MASP1, MASP2, and MASP3 in the lectin pathway. The complement inhibitors can be used alone or in combination to decrease the morbidity and mortality caused by tissue damage associated with ischemia-reperfusion injury or TAAA repair.
Owner:GENENTECH INC
Standard plasmid molecule for detection of genetic improved soybean strain GTS40-3-2 and constructing method thereof
InactiveCN101063171AAvoid missingThe analysis result is accurateMicrobiological testing/measurementGenetic engineeringInternal standardPlasmid
The invention discloses a standard plasmid molecule to check genetic improved soybean strain GTS40-3-2 and constructing method, which comprises the following steps: incorporating strain special fragment of the genetic improved soybean strain GTS40-3-2 and special fragment of soybean internal standard gene Lectin; analyzing exogenesis inserting carrier by-pass ortho gene sequence of genetic improved soybean strain GTS40-3-2; designing strain special PCR primer; augmenting; getting strain special fragment of genetic improved soybean strain GTS40-3-2 and soybean internal standard gene special sequence; constructing into a plasmid molecule with molecular cloning method; getting artificial retooling plasmid molecule pMD-RRS. This standard plasmid molecule can be fit for strain special quantitative PCR analysis and check of genetic improved soybean strain GTS40-3-2 sample.
Owner:SHANGHAI JIAO TONG UNIV
Bone filler material
ActiveUS8506983B2Facilitate re-hydrationPowder deliveryPeptide/protein ingredientsGellan gumFilling materials
Described are bone generation matrixes having an admixture of demineralized bone matrix (DBM) particles and / or bone chips in combination with at least one binding agent selected from the group consisting of alginate, lectin, pectin, gellan gum, starch, collagen and combinations thereof in an aqueous solvent, wherein the DBM particles and / or bone chips are present in an amount of at least 65% by dry weight and the ratio of the aqueous solvent to the dry weight of the DBM particles / bone chips and at least one binding agent is between about 1:1 to about 1:6.
Owner:WARSAW ORTHOPEDIC INC
Novel Modified Galectin 8 Proteins and Use Thereof
InactiveUS20080044385A1More stabilityOrganic active ingredientsFungiEscherichia coliNeutrophil adhesion
Recombinant galectin 8 (rGal 8), produced in host Escherichia coli, exerts hemagglutinating activity, neutrophil adhesion inducing activity, integrin αM-binding activity, proMMP-9 binding activity, active form MMP-9 production promoting activity, superoxide production promoting activity, apoptosis inducing activity for a particular cell, suppressive or inhibitory activity against the metastasis / invasion of tumor cells, etc. In the rGal 8, however, a link domain linking two CRDs is highly susceptible to protease and, therefore, is very easily digestible with the enzyme, thereby losing the above activities. Thus, there is a need for a more stabilized molecule in view of further studies. Modification of the link domain linking two CRDs in galectin 8 provides a modified molecule having an elevated activity without any undesirable effects on the above activities.
Owner:GALPHARMA CO LTD
Magnetic particle tagged blood bank reagents and techniques
InactiveUS20070059782A1Effect separationBiological testingMagnetic immunoreagent carriersMagnetic markerIsotope
Magnets and magnetic particle-labeled reagents are used to capture and / or release magnetic particle-tagged entities for immunohematology diagnostic testing purposes, especially tests performed in blood banking. The magnetic tagged entities may be tagged antibodies, tagged blood cells, tagged universal binding partners, especially tagged lectins and tagged Coombs reagent, and other binding agents such as biotin-avidin, Protein A or G, ligands and their receptors and the like. Separation of unbound material from bound material is effected through the use of one or both the magnetic field effect on the magnetic labeled reactants and the density gradients of layers of an assay construct. Constructs such as chromatographic strip lateral flow format, and liquid phase reactions in suitable vessels with end point determinations that do not require centrifugation to detect reacted entities. Readable labels such as enzymes, fluorophors, chemiluminescent materials, radioactive isotopes, and other labels may be attached to Coombs reagent to provide a readable product of the Coombs reagent with any antibody participating in the assay.
Owner:CHROME RED TECH
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com